Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03096392 · ClinicalTrials.gov registry record · Phase 2
Comparison of Hepatic Directed Vesicle (HDV)-Insulin Lispro Versus Insulin Lispro to Further Improve Glycemic Control
A Phase 2 study of Diabetes Mellitus, Type 1, sponsored by Diasome Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
- 5
- Study locations
NCT03096392 is a Phase 2 study of Diabetes Mellitus, Type 1 that has completed, run by Diasome Pharmaceuticals. The registered enrollment target is 46 participants, below the 1,266-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (96% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT03096392, a Phase 2 study of Diabetes Mellitus, Type 1, has completed, sponsored by Diasome Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
- 5
- Study locations
Study Summary
Multi-Center, double blind, active comparator controlled multiple dose safety, tolerability and efficacy study
Conditions Studied
Interventions
- DRUG HDV insulin lispro 100 UNT/ML
- DRUG Insulin Lispro 100 UNT/ML
Study Locations (5)
Texas
- Texas Diabetes and Endocrinology - Austin
- Texas Diabetes and Endocrinology - Austin
Colorado
- Barbara Davis Center for Diabetes, University of Colorado - Aurora
Florida
- Baptist Diabetes Associates - Miami
North Carolina
- Lucas Research, Inc. - Morehead City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2017-04-18 |
| Est. Completion | 2018-03-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03096392
The ClinicalTrials.gov registry entry for NCT03096392 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,266-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (96% lower). The listed sponsor is Diasome Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetes Mellitus, Type 1 appearing as the primary indexed condition, and to 2 interventions - of which HDV insulin lispro 100 UNT/ML is the first listed.
NCT03096392 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Texas, Colorado, Florida.
Frequently Asked Questions
What is clinical trial NCT03096392 about?
NCT03096392 is a clinical study titled "Comparison of Hepatic Directed Vesicle (HDV)-Insulin Lispro Versus Insulin Lispro to Further Improve Glycemic Control". Multi-Center, double blind, active comparator controlled multiple dose safety, tolerability and efficacy study
What is the current status of trial NCT03096392?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2017-04-18. Estimated completion is 2018-03-18.
What conditions does trial NCT03096392 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 1.
What interventions are being tested in trial NCT03096392?
The interventions under investigation include: HDV insulin lispro 100 UNT/ML (DRUG), Insulin Lispro 100 UNT/ML (DRUG).
Who is sponsoring clinical trial NCT03096392?
This trial is sponsored by Diasome Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03096392 being conducted?
This trial has 5 study locations across Colorado, Florida, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 1
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Islet Transplantation in Type 1 Diabetic Kidney Allograft
RECRUITING · Phase 2
-
Repeat BCG Vaccinations For The Treatment Of Pediatric Type 1 Diabetes
RECRUITING · Phase 2
-
Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec
ACTIVE NOT RECRUITING · Phase 2
-
Diabetes Autoimmunity Withdrawn In New Onset and In Established Patients
ACTIVE NOT RECRUITING · Phase 2
-
Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)
ACTIVE NOT RECRUITING · Phase 2
-
To Examine the Lung When People With Diabetes Take an Inhaled Form of Insulin, Compared to Subcutaneous Insulin.
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.